Virax Biolabs Group Limited (VRAX)
 NASDAQ: VRAX · Real-Time Price · USD
 0.5930
 -0.0044 (-0.74%)
  At close: Oct 30, 2025, 4:00 PM EDT
0.6254
 +0.0324 (5.46%)
  Pre-market: Oct 31, 2025, 4:13 AM EDT
Virax Biolabs Group Stock Forecast
VRAX's stock price has decreased by -72.8% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Virax Biolabs Group stock has a target of 3.00, which predicts a 405.90% increase from the current stock price of 0.59.
Price Target: $3.00 (+405.90%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 31, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Virax Biolabs Group is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | 
|---|---|---|
| Strong Buy | 1 | 1 | 
| Buy | 0 | 0 | 
| Hold | 0 | 0 | 
| Sell | 0 | 0 | 
| Strong Sell | 0 | 0 | 
| Total | 1 | 1 | 
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date | 
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +405.90% | Mar 31, 2025 | 
Financial Forecast
Revenue This Year
 13.76M 
 from 6.33K
 Increased by 217,274.82%
Revenue Next Year
 4.08M 
 from 13.76M
 Decreased by -70.35%
EPS This Year
 0.04 
 from -1.62
EPS Next Year
 n/a 
 from 0.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 
|---|---|---|
| High | 14.2M | 4.2M | 
| Avg | 13.8M | 4.1M | 
| Low | 13.2M | 3.9M | 
Revenue Growth
| Revenue Growth | 2026 | 2027 | 
|---|---|---|
| High | 223,671.9% | -69.5% | 
| Avg | 217,274.8% | -70.4% | 
| Low | 208,745.4% | -71.5% | 
EPS Forecast
| EPS | 2026 | 
|---|---|
| High | 0.04 | 
| Avg | 0.04 | 
| Low | 0.04 | 
EPS Growth
| EPS Growth | 2026 | 
|---|---|
| High | - | 
| Avg | - | 
| Low | - | 
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.